(Q35004475)

5 August 2017

1 reference

title

Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience (English)

1 reference

5 August 2017

main subject

metastatic breast cancer

1 reference

1 reference

Alejandra T Perez

1

1 reference

5 August 2017

Gabriel H Domenech

series ordinal

2

1 reference

5 August 2017

Cynthia Frankel

series ordinal

3

1 reference

5 August 2017

Charles L Vogel

series ordinal

4

1 reference

5 August 2017

publication date

1 January 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

20 Suppl 2

1 reference

5 August 2017

page(s)

22-29

1 reference

Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014883

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014883

Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014883

Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014883

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014883

Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120014883

21 January 2018

Identifiers

DOI

10.1081/CNV-120014883

1 reference

5 August 2017

1 reference